English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Saturday, January 20, 2018
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan
Friday, January 19, 2018
エーザイ、抗がん剤E7046(プロスタグランジンE2受容体タイプ4拮抗剤)についてAdlai Nortye社とライセンス契約を締結
エーザイ・EAファーマ・持田製薬、「グーフィス錠 5mg」の日本においての慢性便秘症に係る製造販売承認を取得
Wednesday, September 23, 2020
Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Friday, September 18, 2020
エーザイ、抗がん剤「ハラヴェン(R)」(エリブリン)リポソーム製剤の臨床第I相試験の最新データを欧州臨床腫瘍学会年次総会において発表
Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
Thursday, September 17, 2020
エーザイ、ベトナムに医薬品販売会社を設立
Eisai Establishes Pharma Sales Subsidiary in Vietnam
Friday, September 11, 2020
エーザイ、欧州臨床腫瘍学会年次総会におけるがん領域の開発品・製品に関する演題を発表
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575